Several nanopharmaceuticals have been developed and are in clinical use or trials:
1. Doxil: This is a liposomal formulation of the chemotherapy drug doxorubicin. The liposome encapsulation reduces the drug's cardiotoxicity and enhances its accumulation in tumor tissues. 2. Abraxane: This is a nanoparticle albumin-bound formulation of paclitaxel, a chemotherapy drug. It improves the drug's solubility and allows for higher doses to be administered without severe side effects. 3. Onivyde: This is a liposomal formulation of irinotecan used for treating metastatic pancreatic cancer. The liposome encapsulation improves the drug's pharmacokinetics and therapeutic index.
